• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/16/21 6:35:46 AM ET
    $ITMR
    Medical/Dental Instruments
    Health Care
    Get the next $ITMR alert in real time by email
    SC 13G 1 zk2125519.htm SC 13G


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    (Amendment No. __)
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d)
    AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
     
    Under the Securities Exchange Act of 1934
     
    ITAMAR MEDICAL LTD
    (Name of Issuer)
     
    Ordinary Shares
    (Title of Class of Securities)
     
     
    465437101
     
    (CUSIP Number)
     
    December 31, 2020
    (Date of Event Which Requires Filing of this Statement)

    Check the following box to designate the rule pursuant to which the Schedule is filed:
     
    ☐ Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP NO.  465437101
     
    1.
    Name of Reporting Person
     
    Migdal Insurance & Financial Holdings Ltd
    2.
    Check the Appropriate Box if a Member of a Group
    (a) ☒
    (b) ☐
    3.
    SEC Use Only
     
     
    4.
    Place of Organization
     
    Israel
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    5.
    Sole Voting Power
     
     
    6.
    Shared Voting Power
     
    23,910,260 Ordinary Shares *
    7.
    Sole Dispositive Power
     
     
    8.
    Shared Dispositive Power
     
    23,910,260 Ordinary Shares *
    9.
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    23,910,260 Ordinary Shares *
    10.
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
    ☐
    11.
    Percent of Class Represented by Amount in Row (9)
     
    5.62%**
    12.
    Type of Reporting Person :               
     
    HC

    *See Item 4.
    ** Based on 425,535,104 ordinary shares issued and outstanding as of December 31, 2020 (according to publicly available information provided by the issuer).

    Page 2 of 5 Pages


    Item 1.


    (a)
    Name of Issuer:
     
    ITAMAR MEDICAL LTD


    (b)
    Address of Issuer’s Principal Executive Offices:
     
    Halamish Street 9 , Caesarea 3088900

    Item 2.
     
    (a)-(c)        Name of Person Filing, address and citizenship:



    The foregoing entity is referred to as the “Reporting Person” in this Statement:



    Migdal Insurance & Financial Holdings Ltd., an Israeli public company, with a principal business address at  4 Efal Street; P.O. Box 3063; Petach Tikva 49512, Israel.
     
    (d)
    Title of Class of Securities:

    Ordinary Shares, NIS 0.01 par value per share (the “Ordinary Shares”)

    (e)
    CUSIP Number:

    465437101 
     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.
     
    Item 4.
    Ownership
     


    Of the 23,910,260 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person (i) 23,910,260 Ordinary Shares are held for members of the public through, among others, provident funds, mutual funds, pension funds and insurance policies, which are managed by direct and indirect subsidiaries of Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii)  3,414,622 Ordinary Shares are held by companies for the management of funds for joint investments in trusteeship, each of which operates under independent management and makes independent voting and investment decisions, and (iii) 0 are beneficially held for their own account (Nostro account). Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of 23,910,260 Ordinary Shares reported in this Statement except as set forth above, see items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which are incorporated herein.
     
    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    See Exhibit below.
     
    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not Applicable.
     
    Page 3 of 5 Pages

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
         
    Exhibit to Item 7
     
    The subsidiaries of reporting person may make independent voting and/or investment decisions for client accounts include:
     
    Subsidiary Name
    Type of Subsidiary
    Migdal Insurance Company ltd.
    FI
    Migdal Makefet Pension and Provident Funds ltd.
    FI
    Yozma Pension Fund for Self Employed Ltd.
    FI
    Migdal Mutual Funds Ltd
    FI
     
    [SIGNATURE PAGE TO FOLLOW]
    Page 4 of 5 Pages

    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    February 11, 2021

     
    MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.

    BY: /s/ Yosef Ben Baruch & Guy Fischer
     authorized signatories of MIGDAL INSURANCE AND FINANCIAL HOLDINGS LTD.

    Page 5 of 5 Pages
    Get the next $ITMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITMR

    DatePrice TargetRatingAnalyst
    9/20/2021$30.00 → $31.00Outperform → Market Perform
    SVB Leerink
    9/15/2021$33.85Buy → Neutral
    Ladenburg Thalmann
    9/14/2021$36.00 → $31.00Buy → Neutral
    HC Wainwright & Co.
    9/14/2021$30.00 → $31.00Outperform → Market Perform
    Cowen & Co.
    More analyst ratings

    $ITMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Brad Fluegel to its Board of Directors

      CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales

      5/24/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Itamar Medical downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously

      9/20/21 6:33:53 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85

      9/15/21 7:36:23 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

      9/14/21 6:31:39 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Financials

    Live finance-specific insights

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

      CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm

      7/28/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    SEC Filings

    See more

    $ITMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 15-12B filed by Itamar Medical Ltd.

      15-12B - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 6:02:01 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:19 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:09 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      10/4/21 6:02:57 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      6/17/21 11:07:03 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Itamar Medical Ltd. (0001613170) (Subject)

      2/16/21 6:35:46 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care